The ErbB2 transmembrane receptor is overexpressed in approximately 30% of human tumors. Mammary gland targeted ErbB2 overexpression is sufficient for mammary tumorigenesis in vivo. The cyclin D1 gene product is overexpressed in 30-50% of human breast cancers. Cyclin D1 anti-sense blocks ErbB2-induced mammary tumor growth and cyclin D1 -/- mice are resistant to ErbB2-induced tumor growth. The PPARgamma nuclear hormone receptor inhibits cellular proliferation and promotes differentiation. Mutations, rearrangements and altered expression of PPARgamma have been identified in several cancers suggesting PPARgamma may function as a tumor suppressor. We have shown cyclin D1 inhibits PPARgamma differentiation function, transactivation and expression in cultured ceils. We have shown CD1 -/- mice have genetic and phenotypic changes reflecting increased PPARgamma expression and activity, implicating increased PPARgamma in the tumor-resistant phenotype. The current studies will determine the molecular mechanisms by which cyclin D1 inhibits PPARgamma signaling in vivo. We will use mammary gland-targeted inducible transgenics to identify the molecular mechanisms by which cyclin D1 regulates PPARgamma function and determine the role of PPARgamma as a mammary gland tumor suppressor in the context of ErbB2. These studies will: 1. Determine the mechanism by which cyclin D1 inhibits PPARgamma transactivation. The ability of cyclin D1 to inhibit a subset of PPARgamma coactivators will be determined. As PPARgamma is acetylated and the cyclin D1 HDAC recruitment domain governs PPARgamma repression, the role of PPARgamma acetylation in repression by cyclin D1 will be determined. 2. Determine the mechanisms by which cyclin D1 inhibits PPARgamma function and expression. Cyclin D1 blocks PPARgamma induced differentiation of fibroblasts to adipocytes. We will identify the domain of cyclin D1 regulating PPARgamma differentiation. Cyclin D1 regulation of PPARgamma will be assessed in CD-/- mice, cyclin E knockin-CD-/- mice and in ponasterone-inducible cyclin D1 anti-sense mice. Correlative expression studies of PPARgamma and cyclin D1 will be conducted in 'benign' breast disease and breast cancers. 3. Determine the role of PPARgamma as a tumor suppressor of ErbB2-induced mammary tumorigenesis. We will determine the functional interactions between ErbB2 and PPARgamma in cultured cells and in ponasterone-inducible mammary gland-targeted PPARgamma transgenic mice. The use of inducible transgenics will allow the determination of PPARgamma function during mammary tumor onset and progression. If PPARgamma is an inhibitor of ErbB2-induced tumorigenesis and PPARgamma tumor suppressor function involves cyclin D1 repression, these studies provide a rational basis for identifying agonists of this interaction for potential therapeutic applications. Moreover, if PPARgamma levels are decreased in precursor lesions of breast cancer, the studies of PPARgamma in benign breast disease may provide a predictor of breast cancer progression. The proposed studies therefore may have important translational implications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107382-02
Application #
6916504
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Spalholz, Barbara A
Project Start
2004-07-02
Project End
2005-11-30
Budget Start
2005-06-23
Budget End
2005-11-30
Support Year
2
Fiscal Year
2005
Total Cost
$58,997
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Zhao, Qian; Deng, Shengqiong; Wang, Guangxue et al. (2016) A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget 7:21865-74
Ju, Xiaoming; Jiao, Xuanmao; Ertel, Adam et al. (2016) v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res 76:6723-6734
Ma, Haizhong; Liang, Chunli; Wang, Guangxue et al. (2014) MicroRNA-mediated cancer metastasis regulation via heterotypic signals in the microenvironment. Curr Pharm Biotechnol 15:455-8
Sicoli, Daniela; Jiao, Xuanmao; Ju, Xiaoming et al. (2014) CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res 74:7103-14
Li, Yuan; Liang, Chunli; Ma, Haizhong et al. (2014) miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19:7122-37
Velasco-Velázquez, Marco; Xolalpa, Wendy; Pestell, Richard G (2014) The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets 18:1265-75
Yu, Zuoren; Xu, Zengguang; Disante, Gabriele et al. (2014) miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 5:1083-90
Yu, Zuoren; Wang, Liping; Wang, Chenguang et al. (2013) Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. Nat Commun 4:2812
Ju, Xiaoming; Ertel, Adam; Casimiro, Mathew C et al. (2013) Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res 73:978-89

Showing the most recent 10 out of 101 publications